The proportion of patients with serious infections occurring over the first 22 weeks of the trial
The proportion of patients with infections & atypical/opportunistic infections. The duration of most frequently reported infections. Proportion of patients achieving ACR 20 criteria at 22 weeks. Effect of 1.5 mg/kg dose increment in reducing disease
18 Years and older (Adult, Senior)
May 10, 2002
May 19, 2011
† Study has passed its completion date and status has not been verified in more than two years.